Corbus Pharmaceuticals Holdings, Inc., was incorporated under the laws of the State of Delaware on April 24, 2009. Corbus is a precision oncology company with a diverse product portfolio dedicated to helping people beat serious diseases by bringing innovative scientific methods to widely understood biological pathways. The company's pipeline consists of two experimental drugs for solid tumors: CRB-701, a next-generation antibody-drug conjugate that targets the expression of Nectin-4 on cancer cells to release cytotoxic payloads, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells.